New trends on obesity and NAFLD in Asia

Journal of Hepatology

Volumn 67, Issue 4, 2017, Pages 862-873

  Fan, Jian Gao ^a   Kim, Seung Up ^b   Wong, Vincent Wai Sun ^c  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Yonsei University College of Medicine   (South Korea)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Body mass index; China; Fatty liver; Korea; Non alcoholic steatohepatitis; Waist circumference

Indexed keywords

ASIA; BARIATRIC SURGERY; CHRONIC HEPATITIS B; CLINICAL ASSESSMENT; DIET SUPPLEMENTATION; EPIDEMIOLOGICAL DATA; FATTY LIVER; GENETICS; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LIVER DISEASE; MANAGED CARE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PHARMACEUTICAL CARE; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SARCOPENIA; SEDENTARY LIFESTYLE; THERAPY EFFECT; BODY MASS; COMPLICATION; DIET; GENETIC PREDISPOSITION;

ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ASIA; BODY MASS INDEX; DIET; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LIPASE; MEMBRANE PROTEINS; METABOLIC SYNDROME; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREVALENCE; RISK FACTORS; SARCOPENIA; SEDENTARY LIFESTYLE;

EID: 85026462124     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.06.003     Document Type: Review

References (150)

1. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
2. Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
3. Younossi, Z.M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
4. Fan, J.G., Farrell, G.C., Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 50 (2009), 204–210.
5. World Health Organization. http://www.who.int/mediacentre/factsheets/fs311/en/, accessed on 2 Feb 2017.
6. Chan, J.C., Malik, V., Jia, W., Kadowaki, T., Yajnik, C.S., Yoon, K.H., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301 (2009), 2129–2140.
7. Consultation, W.H.O.E., Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (2004), 157–163.
8. Visscher, T.L., Seidell, J.C., Molarius, A., van der Kuip, D., Hofman, A., Witteman, J.C., A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study. Int J Obes Relat Metab Disord 25 (2001), 1730–1735.
9. Alberti, K.G., Eckel, R.H., Grundy, S.M., Zimmet, P.Z., Cleeman, J.I., Donato, K.A., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120 (2009), 1640–1645.
10. Organization WH. Global Health Observatory (GHO) data – Overweight and obesity; 2014.
11. Eguchi, Y., Hyogo, H., Ono, M., Mizuta, T., Ono, N., Fujimoto, K., et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 47 (2012), 586–595.
12. Nishioji, K., Sumida, Y., Kamaguchi, M., Mochizuki, N., Kobayashi, M., Nishimura, T., et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011–2012. J Gastroenterol 50 (2015), 95–108.
13. Farrell, G.C., Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?. J Gastroenterol Hepatol 18 (2003), 124–138.
14. Nayak, N.C., Vasdev, N., Saigal, S., Soin, A.S., End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol 41 (2010), 425–430.
15. Okanoue, T., Umemura, A., Yasui, K., Itoh, Y., Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol 26 (2011), 153–162.
16. Li, J., Fan, S., Li, Y., Chen, J., Cao, J., Huang, J., et al. Incidence of obesity and its modifiable risk factors in Chinese adults aged 35-74 years: a prospective cohort study. Zhonghua Liu Xing Bing Xue Za Zhi 35 (2014), 349–353.
17. Matsushita, Y., Takahashi, Y., Mizoue, T., Inoue, M., Noda, M., Tsugane, S., Overweight and obesity trends among Japanese adults: a 10-year follow-up of the JPHC Study. Int J Obes 32 (2008), 1861–1867.
18. Xu, C., Yu, C., Ma, H., Xu, L., Miao, M., Li, Y., Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. Am J Gastroenterol 108 (2013), 1299–1304.
19. Stevens, G.A., Singh, G.M., Lu, Y., Danaei, G., Lin, J.K., Finucane, M.M., et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr, 10, 2012, 22.
20. Chakraborty, C., Das, S., Dynamics of diabetes and obesity: an alarming situation in the developing countries in Asia. Mini Rev Med Chem 16 (2016), 1258–1268.
21. Pradeepa, R., Anjana, R.M., Joshi, S.R., Bhansali, A., Deepa, M., Joshi, P.P., et al. Prevalence of generalized & abdominal obesity in urban & rural India–the ICMR-INDIAB Study (Phase-I) (Trans.) ICMR- NDIAB-3 Indian J Med Res 142 (2015), 139–150.
22. Li, Z., Xue, J., Chen, P., Chen, L., Yan, S., Liu, L., Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol 29 (2014), 42–51.
23. Wang, M.M., Wang, G.S., Shen, F., Chen, G.Y., Pan, Q., Fan, J.G., Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci 59 (2014), 2571–2579.
24. Majumdar, A., Misra, P., Sharma, S., Kant, S., Krishnan, A., Pandav, C.S., Prevalence of nonalcoholic fatty liver disease in an adult population in a rural community of Haryana, India. Indian J Public Health 60 (2016), 26–33.
25. Anurag, L., Aniket, S., Shalik, J., Amarja, L., Dhananjay, R., Sachin, J., Non-alcoholic fatty liver disease prevalence and associated risk factors–A study from rural sector of Maharashtra. Trop Gastroenterol 36 (2015), 25–30.
26. Patel, S.A., Ali, M.K., Alam, D., Yan, L.L., Levitt, N.S., Bernabe-Ortiz, A., et al. Obesity and its relation with diabetes and hypertension: a cross-sectional study across 4 geographical regions. Glob Heart 11 (2016), 71–79 e74.
27. Anderson, E.L., Howe, L.D., Jones, H.E., Higgins, J.P., Lawlor, D.A., Fraser, A., The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One, 10, 2015, e0140908.
28. Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
29. Mabry, R.M., Winkler, E.A., Reeves, M.M., Eakin, E.G., Owen, N., Associations of physical activity and sitting time with the metabolic syndrome among Omani adults. Obesity 20 (2012), 2290–2295.
30. Matthews, C.E., George, S.M., Moore, S.C., Bowles, H.R., Blair, A., Park, Y., et al. Amount of time spent in sedentary behaviors and cause-specific mortality in US adults. Am J Clin Nutr 95 (2012), 437–445.
31. Ryu, S., Chang, Y., Jung, H.S., Yun, K.E., Kwon, M.J., Choi, Y., et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J Hepatol 63 (2015), 1229–1237.
32. Lim, S., Kim, J.H., Yoon, J.W., Kang, S.M., Choi, S.H., Park, Y.J., et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 33 (2010), 1652–1654.
33. Lee, Y.H., Jung, K.S., Kim, S.U., Yoon, H.J., Yun, Y.J., Lee, B.W., et al. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008–2011). J Hepatol 63 (2015), 486–493.
34. Lee, Y.H., Kim, S.U., Song, K., Park, J.Y., Kim, D.Y., Ahn, S.H., et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008–2011). Hepatology 63 (2016), 776–786.
35. Koo, B.K., Kim, D., Joo, S.K., Kim, J.H., Chang, M.S., Kim, B.G., et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 66 (2017), 123–131.
36. Hashimoto, Y., Osaka, T., Fukuda, T., Tanaka, M., Yamazaki, M., Fukui, M., The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes. Endocr J 63 (2016), 877–884.
37. Petta, S., Ciminnisi, S., Di Marco, V., Cabibi, D., Camma, C., Licata, A., et al. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 45 (2017), 510–518.
38. Ko, B.J., Park, K.H., Mantzoros, C.S., Diet patterns, adipokines, and metabolism: where are we and what is next?. Metabolism 63 (2014), 168–177.
39. McCarthy, E.M., Rinella, M.E., The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet 112 (2012), 401–409.
40. Fan, J.G., Cao, H.X., Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 28 (2013), 81–87.
41. Mouzaki, M., Allard, J.P., The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol 46 (2012), 457–467.
42. Oya, J., Nakagami, T., Sasaki, S., Jimba, S., Murakami, K., Kasahara, T., et al. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. Eur J Clin Nutr 64 (2010), 1179–1185.
43. Li, Y.H., Yang, L.H., Sha, K.H., Liu, T.G., Zhang, L.G., Liu, X.X., Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis. World J Gastroenterol 21 (2015), 7008–7013.
44. Yang, C.Q., Shu, L., Wang, S., Wang, J.J., Zhou, Y., Xuan, Y.J., et al. Dietary patterns modulate the risk of non-alcoholic fatty liver disease in Chinese adults. Nutrients 7 (2015), 4778–4791.
45. Chan, R., Wong, V.W., Chu, W.C., Wong, G.L., Li, L.S., Leung, J., et al. Diet-quality scores and prevalence of nonalcoholic fatty liver disease: a population study using proton-magnetic resonance spectroscopy. PLoS One, 10, 2015, e0139310.
46. Han, J.M., Jo, A.N., Lee, S.M., Bae, H.S., Jun, D.W., Cho, Y.K., et al. Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 29 (2014), 1265–1272.
47. Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Blendis, L., Halpern, Z., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47 (2007), 711–717.
48. Jia, Q., Xia, Y., Zhang, Q., Wu, H., Du, H., Liu, L., et al. Dietary patterns are associated with prevalence of fatty liver disease in adults. Eur J Clin Nutr 69 (2015), 914–921.
49. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
50. Li, Y., Xing, C., Cohen, J.C., Hobbs, H.H., Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology 55 (2012), 327–328.
51. Shen, J., Wong, G.L., Chan, H.L., Chan, H.Y., Yeung, D.K., Chan, R.S., et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 39 (2014), 532–539.
52. Kawaguchi, T., Sumida, Y., Umemura, A., Matsuo, K., Takahashi, M., Takamura, T., et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One, 7, 2012, e38322.
53. Tai, C.M., Huang, C.K., Tu, H.P., Hwang, J.C., Yeh, M.L., Huang, C.F., et al. Interactions of a PPARGC1A variant and a PNPLA3 variant affect nonalcoholic steatohepatitis in severely obese Taiwanese patients. Medicine, 95, 2016, e3120.
54. Park, J.-H., Cho, B., Kwon, H., Prilutsky, D., Yun, J.M., Choi, H.C., et al. I148 M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int 35 (2014), 2537–2546.
55. Kowdley, K.V., Belt, P., Wilson, L.A., Yeh, M.M., Neuschwander-Tetri, B.A., Chalasani, N., et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 55 (2012), 77–85.
56. Graham, R.M., Chua, A.C., Carter, K.W., Delima, R.D., Johnstone, D., Herbison, C.E., et al. Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology 52 (2010), 462–471.
57. Duseja, A., Das, R., Nanda, M., Das, A., Garewal, G., Chawla, Y., Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 11 (2005), 393–395.
58. Valenti, L., Fracanzani, A.L., Bugianesi, E., Dongiovanni, P., Galmozzi, E., Vanni, E., et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 138 (2010), 905–912.
59. Millera, M., Rhynea, J., Chena, H., Beacha, V., Ericsona, R., et al. APOC3 promoter polymorphisms C-482T and T-455 C are associated with the metabolic syndrome. Arch Med Res 38 (2007), 444–451.
60. Petersen, K.F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J.N., Zhang, X.M., et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 362 (2010), 1082–1089.
61. Kozlitina, J., Boerwinkle, E., Cohen, J.C., Hobbs, H.H., Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 53 (2011), 467–474.
62. Valenti, L., Nobili, V., Al-Serri, A., Rametta, R., Leathart, J.B., Zappa, M.A., et al. The APOC3T-455 C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 55 (2011), 1409–1414.
63. Wong, V.W., Wong, G.L., Tse, C.H., Chan, H.L., Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. J Hepatol 61 (2014), 708–709.
64. Pirola, C.J., Sookoian, S., The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology 62 (2015), 1742–1756.
65. Wong, V.W., Chu, W.C., Wong, G.L., Chan, R.S., Chim, A.M., Ong, A., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61 (2012), 409–415.
66. Fung, J., Lee, C.K., Chan, M., Seto, W.K., Lai, C.L., Yuen, M.F., et al. High prevalence of non-alcoholic fatty liver disease in the Chinese - results from the Hong Kong liver health census. Liver Int 35 (2015), 542–549.
67. Goh, S.C., Ho, E.L., Goh, K.L., Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatol Int 7 (2013), 548–554.
68. Chou, T.C., Liang, W.M., Wang, C.B., Wu, T.N., Hang, L.W., Obstructive sleep apnea is associated with liver disease: a population-based cohort study. Sleep Med 16 (2015), 955–960.
69. Huang, H.-L., Lin, W.-Y., Lee, L.-T., Wang, H.-H., Lee, W.-J., Huang, K.-C., Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 17 (2007), 1457–1463.
70. Park, S.H., Kim, B.I., Yun, J.W., Kim, J.W., Park, D.I., Cho, Y.K., et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 19 (2004), 694–698.
71. Chang, Y., Jung, H.S., Yun, K.E., Cho, J., Cho, Y.K., Ryu, S., Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol 108 (2013), 1861–1868.
72. Anty, R., Hastier, A., Canivet, C.M., Patouraux, S., Schneck, A.S., Ferrari-Panaia, P., et al. Severe vitamin D deficiency is not associated with liver damage in morbidly obese patients. Obes Surg 26 (2016), 2138–2143.
73. Tao, Y., Gu, H., Wu, J., Sui, J., Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects. Endocr Res 40 (2015), 74–78.
74. Lee, K.W., Bang, K.B., Rhee, E.J., Kwon, H.J., Lee, M.Y., Cho, Y.K., Impact of hypothyroidism on the development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study. Clin Mol Hepatol 21 (2015), 372–378.
75. Fan, J.G., Zhu, J., Li, X.J., Chen, L., Li, L., Dai, F., et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 43 (2005), 508–514.
76. Das, K., Das, K., Mukherjee, P.S., Ghosh, A., Ghosh, S., Mridha, A.R., et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51 (2010), 1593–1602.
77. Kwon, Y.M., Oh, S.W., Hwang, S.S., Lee, C., Kwon, H., Chung, G.E., Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 107 (2012), 1852–1858.
78. Wei, J.L., Leung, J.C., Loong, T.C., Wong, G.L., Yeung, D.K., Chan, R.S., et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol 110 (2015), 1306–1314 [Quiz 1315].
79. Younossi, Z.M., Stepanova, M., Negro, F., Hallaji, S., Younossi, Y., Lam, B., et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 91 (2012), 319–327.
80. Dela Cruz, A.C., Bugianesi, E., George, J., Day, C.P., Liaquat, H., Charatcharoenwitthaya, P., et al. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. Gastroenterology, 146, 2014, S-909.
81. Leung, J.C., Loong, T.C., Wei, J.L., Wong, G.L., Chan, A.W., Choi, P.C., et al. Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology 65 (2017), 54–64.
82. Wong, V.W., Wong, G.L., Yeung, D.K., Lau, T.K., Chan, C.K., Chim, A.M., et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 62 (2015), 182–189.
83. Giudice, E.M., Grandone, A., Cirillo, G., Santoro, N., Amato, A., Brienza, C., et al. The association of PNPLA3 variants with liver enzymes in childhood obesity is driven by the interaction with abdominal fat. PLoS One, 6, 2011, e27933.
84. Graff, M., North, K.E., Franceschini, N., Reiner, A.P., Feitosa, M., Carr, J.J., et al. PNPLA3 gene-by-visceral adipose tissue volume interaction and the pathogenesis of fatty liver disease: the NHLBI family heart study. Int J Obes 37 (2013), 432–438.
85. Feldman, A., Eder, S.K., Felder, T.K., Kedenko, L., Paulweber, B., Stadlmayr, A., et al. Clinical and metabolic characterization of lean Caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol 112 (2017), 102–110.
86. Wong, V.W., Hui, A.Y., Tsang, S.W., Chan, J.L., Wong, G.L., Chan, A.W., et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 24 (2006), 1215–1222.
87. Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 107 (2012), 253–261.
88. Wong, V.W., Wong, G.L., Yeung, J.C., Fung, C.Y., Chan, J.K., Chang, Z.H., et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology 63 (2016), 754–763.
89. Goh, G.B., Chang, P.E., Tan, C.K., Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol 29 (2015), 919–928.
90. Tateishi, R., Okanoue, T., Fujiwara, N., Okita, K., Kiyosawa, K., Omata, M., et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol 50 (2015), 350–360.
91. Bruix, J., Sherman, M., American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
92. European Association For The Study Of The Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
93. Omata, M., Lesmana, L.A., Tateishi, R., Chen, P.J., Lin, S.M., Yoshida, H., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4 (2010), 439–474.
94. Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arii, S., Imai, Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9 (2011), 428–433 [Quiz e450].
95. Mittal, S., El-Serag, H.B., Sada, Y.H., Kanwal, F., Duan, Z., Temple, S., et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 14 (2016), 124–131 e121.
96. Chan, A.W., Yu, S., Yu, Y.H., Tong, J.H., Wang, L., Tin, E.K., et al. Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. Histopathology 69 (2016), 971–984.
97. Salomao, M., Yu, W.M., Brown, R.S. Jr., Emond, J.C., Lefkowitch, J.H., Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34 (2010), 1630–1636.
98. Hang, L.W., Chen, C.F., Wang, C.B., Wu, T.N., Liang, W.M., Chou, T.C., The association between continuous positive airway pressure therapy and liver disease development in obstructive sleep apnea/hypopnea syndrome patients: a nationwide population-based cohort study in Taiwan. Sleep Breath 21 (2017), 461–467.
99. Wong, V.W., Wong, G.L., Tsang, S.W., Fan, T., Chu, W.C., Woo, J., et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 60 (2011), 829–836.
100. Adams, L.A., Anstee, Q.M., Tilg, H., Targher, G., Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66 (2017), 1138–1153.
101. Leung, C.M., Lai, L.S., Wong, W.H., Chan, K.H., Luk, Y.W., Lai, J.Y., et al. Non-alcoholic fatty liver disease: an expanding problem with low levels of awareness in Hong Kong. J Gastroenterol Hepatol 24 (2009), 1786–1790.
102. de Silva, H.J., Dassanayake, A.S., Non-alcoholic fatty liver disease: confronting the global epidemic requires better awareness. J Gastroenterol Hepatol 24 (2009), 1705–1707.
103. Kallman, J.B., Arsalla, A., Park, V., Dhungel, S., Bhatia, P., Haddad, D., et al. Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Aliment Pharmacol Ther 29 (2009), 1019–1024.
104. Grattagliano, I., D'Ambrosio, G., Palmieri, V.O., Moschetta, A., Palasciano, G., Portincasa, P., Improving nonalcoholic fatty liver disease management by general practitioners: a critical evaluation and impact of an educational training program. J Gastrointestin Liver Dis 17 (2008), 389–394.
105. Wong, V.W., Chan, R.S., Wong, G.L., Cheung, B.H., Chu, W.C., Yeung, D.K., et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 59 (2013), 536–542.
106. Jin, Y.J., Kim, K.M., Hwang, S., Lee, S.G., Ha, T.Y., Song, G.W., et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. J Gastroenterol Hepatol 27 (2012), 1341–1347.
107. Takahashi, A., Abe, K., Usami, K., Imaizumi, H., Hayashi, M., Okai, K., et al. Simple resistance exercise helps patients with non-alcoholic fatty liver disease. Int J Sports Med 36 (2015), 848–852.
108. Zhang, H.J., He, J., Pan, L.L., Ma, Z.M., Han, C.K., Chen, C.S., et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern Med 176 (2016), 1074–1082.
109. Zhang, H.J., Pan, L.L., Ma, Z.M., Chen, Z., Huang, Z.F., Sun, Q., et al. Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: A 1-year follow-up study. Diabetes Obes Metab 19 (2017), 284–289.
110. Oh, S., So, R., Shida, T., Matsuo, T., Kim, B., Akiyama, K., et al. High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. Sci Rep, 7, 2017, 43029.
111. Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J Hepatol 66 (2017), 142–152.
112. Golabi, P., Locklear, C.T., Austin, P., Afdhal, S., Byrns, M., Gerber, L., et al. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol 22 (2016), 6318–6327.
113. Bellentani, S., Dalle Grave, R., Suppini, A., Marchesini, G., Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 47 (2008), 746–754.
114. Whitsel, L.P., Government's role in promoting healthy living. Prog Cardiovasc Dis 59 (2017), 492–497.
115. Xinhua News Agency. Healthy China 2030 Project. http://news.xinhuanet.com/health/2016-10/25/c_1119786029.htm (accessed on 31 May 2017).
116. Choo, J., Yoon, S.J., Ryu, H., Park, M.S., Lee, H.S., Park, Y.M., et al. The Seoul metropolitan lifestyle intervention program and metabolic syndrome risk: a retrospective database study. Int J Environ Res Public Health, 13, 2016, E667.
117. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
118. Klebanoff, M.J., Corey, K.E., Chhatwal, J., Kaplan, L.M., Chung, R.T., Hur, C., Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis. Hepatology 65 (2016), 1156–1164.
119. Kasama, K., Mui, W., Lee, W.J., Lakdawala, M., Naitoh, T., Seki, Y., et al. IFSO-APC consensus statements 2011. Obes Surg 22 (2012), 677–684.
120. Angrisani, L., Santonicola, A., Iovino, P., Formisano, G., Buchwald, H., Scopinaro, N., Bariatric surgery worldwide 2013. Obes Surg 25 (2015), 1822–1832.
121. Kumar, N., Choudhary, N.S., Treating morbid obesity in cirrhosis: A quest of holy grail. World J Hepatol 7 (2015), 2819–2828.
122. Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55 (2012), 2005–2023.
123. Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
124. Nelson, N.P., Easterbrook, P.J., McMahon, B.J., Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis 20 (2016), 607–628.
125. Peng, D., Han, Y., Ding, H., Wei, L., Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 23 (2008), 1082–1088.
126. Shi, J.P., Fan, J.G., Wu, R., Gao, X.Q., Zhang, L., Wang, H., et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 23 (2008), 1419–1425.
127. Minakari, M., Molaei, M., Shalmani, H.M., Mohammad Alizadeh, A.H., Jazi, A.H., Naderi, N., et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol 21 (2009), 512–516.
128. Yun, J.W., Cho, Y.K., Park, J.H., Kim, H.J., Park, D.I., Sohn, C.I., et al. Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis B. Liver Int 29 (2009), 878–883.
129. Xu, Q.H., Jie, Y.S., Shu, X., Chen, L.B., Cao, H., Li, G., [Relationship of fatty liver with HBV infection, hyperlipidemia and abnormal alanine aminotransferase]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 23 (2009), 141–143.
130. Wong, V.W., Wong, G.L., Yu, J., Choi, P.C., Chan, A.W., Chan, H.Y., et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 105 (2010), 132–138.
131. Zheng, R.D., Xu, C.R., Jiang, L., Dou, A.X., Zhou, K., Lu, L.G., Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. Int J Med Sci 7 (2010), 272–277.
132. Rastogi, A., Sakhuja, P., Kumar, A., Hissar, S., Jain, A., Gondal, R., et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol 54 (2011), 454–459.
133. Wong, V.W., Wong, G.L., Chu, W.C., Chim, A.M., Ong, A., Yeung, D.K., et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 56 (2012), 533–540.
134. Cheng, Y.L., Wang, Y.J., Kao, W.Y., Chen, P.H., Huo, T.I., Huang, Y.H., et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One, 8, 2013, e72049.
135. Ding, W.J., Wang, M.M., Wang, G.S., Shen, F., Qin, J.J., Fan, J.G., Thyroid function is associated with non-alcoholic fatty liver disease in chronic hepatitis B-infected subjects. J Gastroenterol Hepatol 30 (2015), 1753–1758.
136. Charatcharoenwitthaya, P., Pongpaibul, A., Kaosombatwattana, U., Bhanthumkomol, P., Bandidniyamanon, W., Pausawasdi, N., et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int 37 (2016), 542–551.
137. Joo, E.J., Chang, Y., Yeom, J.S., Ryu, S., Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology 65 (2017), 828–835.
138. Farrell, G.C., Wong, V.W., Chitturi, S., NAFLD in Asia–as common and important as in the West. Nat Rev Gastroenterol Hepatol 10 (2013), 307–318.
139. Luo, B., Wang, Y., Wang, K., Association of metabolic syndrome and hepatitis B infection in a Chinese population. Clin Chim Acta 380 (2007), 238–240.
140. Machado, M.V., Oliveira, A.G., Cortez-Pinto, H., Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 26 (2011), 1361–1367.
141. Wang, C.C., Hsu, C.S., Liu, C.J., Kao, J.H., Chen, D.S., Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 23 (2008), 779–782.
142. Kim, K.H., Shin, H.J., Kim, K., Choi, H.M., Rhee, S.H., Moon, H.B., et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 132 (2007), 1955–1967.
143. Chan, A.W., Wong, G.L., Chan, H.Y., Tong, J.H., Yu, Y.H., Choi, P.C., et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol 32 (2017), 667–676.
144. Wong, G.L., Wong, V.W., Choi, P.C., Chan, A.W., Chim, A.M., Yiu, K.K., et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 58 (2009), 111–117.
145. Lee, J., Yoo, S.H., Sohn, W., Kim, H.W., Choi, Y.S., Won, J.H., et al. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. Clin Mol Hepatol 22 (2016), 339–349.
146. Chen, C.L., Yang, H.I., Yang, W.S., Liu, C.J., Chen, P.J., You, S.L., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135 (2008), 111–121.
147. Li, Q., Li, W.W., Yang, X., Fan, W.B., Yu, J.H., Xie, S.S., et al. Type 2 diabetes and hepatocellular carcinoma: a case-control study in patients with chronic hepatitis B. Int J Cancer 131 (2012), 1197–1202.
148. Ko, W.H., Chiu, S.Y., Yang, K.C., Chen, H.H., Diabetes, hepatitis virus infection and hepatocellular carcinoma: A case-control study in hepatitis endemic area. Hepatol Res 42 (2012), 774–781.
149. Kim, J.H., Sinn, D.H., Gwak, G.Y., Kang, W., Paik, Y.H., Choi, M.S., et al. Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. J Gastroenterol Hepatol 32 (2017), 1100–1106.
150. Zhai, H.L., Wang, N.J., Han, B., Li, Q., Chen, Y., Zhu, C.F., et al. Low vitamin D levels and non-alcoholic fatty liver disease, evidence for their independent association in men in East China: a cross-sectional study (Survey on Prevalence in East China for Metabolic Diseases and Risk Factors (SPECT-China)). Br J Nutr 115 (2016), 1352–1359.